Abstract |
The effect of Danazol, a synthetic gonadotropin inhibitor, on two groups of Sprague-Dawley rats with dimethylbenze (a) anthracine (DMBA) induced mammary carcinoma was studied. Twenty-four (83%) of 29 control animals developed mammary tumors. Forty-four rats in one treatment group received Danazol after tumor reached 0.5 cm in diameter. Twenty-nine (66%) demonstrated tumor regression (p less than 0.005) and in 16 (36%) tumor disappeared (p less than 0.005). In a second treatment group (given Danazol daily after administration of DMBA), only seven of 50 rats (14%) developed palpable mammary carcinoma (p less than 0.0005). Danazol therapy resulted in regression of established mammary carcinoma in rats, and produced a striking inhibition of carcinogenesis in those animals treated from the time DMBA was administered. Danazol is clinically safe; studies using it in the treatment of breast cancer in women who are candidates for hormonal ablative therapy seem warranted.
|
Authors | T G Peters, J D Lewis, E J Wilkinson, T M Fuhrman |
Journal | Cancer
(Cancer)
Vol. 40
Issue 6
Pg. 2797-800
(Dec 1977)
ISSN: 0008-543X [Print] United States |
PMID | 412578
(Publication Type: Journal Article)
|
Chemical References |
- Hormones
- Pregnadienes
- 9,10-Dimethyl-1,2-benzanthracene
- Danazol
|
Topics |
- 9,10-Dimethyl-1,2-benzanthracene
- Animals
- Danazol
(administration & dosage, therapeutic use)
- Endocrine Glands
(physiopathology)
- Female
- Hormones
(physiology)
- Mammary Neoplasms, Experimental
(chemically induced, drug therapy, physiopathology)
- Pregnadienes
(therapeutic use)
- Rats
- Remission, Spontaneous
|